adenine has been researched along with Chemical Dependence in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phase I, open-label, fixed-sequence, pharmacokinetic drug-drug interaction study." | 2.71 | Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. ( Berenson, CS; Booker, BM; Bullock, JM; Cloen, D; Coakley, DF; Flaherty, JF; Haas, CE; Kearney, BP; Liaw, S; Smith, PF; Yale, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, M | 1 |
| Vanichseni, S | 1 |
| Suntharasamai, P | 1 |
| Sangkum, U | 1 |
| Mock, PA | 1 |
| Leethochawalit, M | 1 |
| Chiamwongpaet, S | 1 |
| Gvetadze, RJ | 1 |
| Kittimunkong, S | 1 |
| Curlin, ME | 1 |
| Worrajittanon, D | 1 |
| McNicholl, JM | 1 |
| Paxton, LA | 1 |
| Choopanya, K | 1 |
| Smith, PF | 1 |
| Kearney, BP | 1 |
| Liaw, S | 1 |
| Cloen, D | 1 |
| Bullock, JM | 1 |
| Haas, CE | 1 |
| Yale, K | 1 |
| Booker, BM | 1 |
| Berenson, CS | 1 |
| Coakley, DF | 1 |
| Flaherty, JF | 1 |
| Chua, A | 1 |
| Ford, N | 1 |
| Wilson, D | 1 |
| Cawthorne, P | 1 |
| Franke, P | 1 |
| Wang, T | 1 |
| Nöthen, MM | 1 |
| Knapp, M | 1 |
| Neidt, H | 1 |
| Albrecht, S | 1 |
| Jahnes, E | 1 |
| Propping, P | 1 |
| Maier, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand[NCT00119106] | Phase 2/Phase 3 | 2,413 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean number of days that participants took study drug based on study drug diaries by study group. (NCT00119106)
Timeframe: Participants were asked about adherence at 3 month visits, up to 6.9 years.
| Intervention | days (Mean) |
|---|---|
| Tenofovir | 84 |
| Placebo | 84 |
Number of Participants with adverse clinical events in tenofovir and placebo arms (NCT00119106)
Timeframe: Up to 6.9 years
| Intervention | participants (Number) |
|---|---|
| Tenofovir | 1098 |
| Placebo | 1083 |
Plasma HIV RNA concentrations. (NCT00119106)
Timeframe: Among people who seroconverted, viral load was measured at month 1, 2, and every 4 months after HIV seroconversion
| Intervention | Copies/mL (Mean) |
|---|---|
| Tenofovir | 929829 |
| Placebo | 120061 |
"Number of Participants reporting injecting and sharing needles:~Assessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing." (NCT00119106)
Timeframe: Participants were asked about injecting and needle sharing behaviors at enrollment and every 3 month visit, up to 6.9 years
| Intervention | participants (Number) |
|---|---|
| Tenofovir | 58 |
| Placebo | 59 |
Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups. (NCT00119106)
Timeframe: Specimens collected at the time of HIV seroconversion
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir | 0 |
| Placebo | 0 |
Number of participants (NCT00119106)
Timeframe: At enrolment
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir Group | 251 |
| Placebo Group | 271 |
Kaplan Meier survival curve. (NCT00119106)
Timeframe: From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years
| Intervention | Infections/ 100 person-years (Number) |
|---|---|
| Tenofovir | 17 |
| Placebo | 33 |
Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities (NCT00119106)
Timeframe: Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years
| Intervention | participants (Number) |
|---|---|
| Tenofovir | 3 |
| Placebo | 3 |
2 trials available for adenine and Chemical Dependence
| Article | Year |
|---|---|
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle A | 2014 |
Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
Topics: Adenine; Adult; Area Under Curve; Chromatography, High Pressure Liquid; Confidence Intervals; Drug I | 2004 |
3 other studies available for adenine and Chemical Dependence
| Article | Year |
|---|---|
Tenofovir helps prevent HIV in drug users.
Topics: Adenine; Anti-HIV Agents; Drug Users; HIV Infections; Humans; Organophosphonates; Substance-Related | 2013 |
The tenofovir pre-exposure prophylaxis trial in Thailand: researchers should show more openness in their engagement with the community.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community Networks; HIV Infections; Human Rights | 2005 |
Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence.
Topics: Adenine; Adult; Alcoholism; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to | 2001 |